Transcriptional regulation of the BRCA1 proximal promoter has been suggested to play a role in the decreased expression of BRCA1 observed in sporadic breast cancer. Computer analysis of the sequence of the proximal promoter reveals the presence of a potential CREB site. We have identi®ed CREB/ATF-1 as the factor interacting with this site in nuclear extracts from MCF-7 and T-47D cells. This site is shown to be important for the constitutive expression of the promoter in these cells, as well as in Hep G2 cells. Despite the presence of this site, the BRCA1 promoter is not responsive to cAMP induction. It appears that CREB acts as a constitutive positive element for BRCA1 expression and that any mechanism inactivating CREB function would have a dramatic eect on BRCA1 expression. Oncogene (2001) 20, 7110 ± 7114.
The BRCA1 gene was isolated using a classic positional cloning approach, and was the ®rst gene directly identi®ed as a breast cancer susceptibility gene . Since then, more than 200 mutations throughout the entire coding region have been identi®ed and correlated with hereditary cases of breast and ovarian cancers. The product of the BRCA1 gene is a 220 kD phosphoprotein which localizes mainly in the nucleus (Scully et al., 1996) and whose expression level and phosphorylation status are cell cycle dependent (Chen et al., 1996) . It contains a RING-®nger motif close to the NH 2 terminus (Miki et al., 1994) , which is thought to function as a ubiquitin ligase (Lorick et al., 1999) , and two C-terminal domains which are involved in transcriptional activation (Chapman and Verma, 1996) . BRCA1 has also been shown to associate with the RNA polymerase II holoenzyme (Scully et al., 1997a) and with CBP/p300 (Cui et al., 1998) , suggesting a possible function in transcriptional regulation. Furthermore, BRCA1 has been shown to transactivate the p21
Waf1 promoter and to directly interact with p53 (Zhang et al., 1998) . The involvement of BRCA1 in DNA repair and cell cycle control has been suggested by its ability to interact with RAD51 (Scully et al., 1997b ) and RAD50; the increased sensitivity of murine embryos carrying a null mutation of BRCA1 to gamma radiation (Shen et al., 1998) ; and recent studies in which BRCA1 de®cient embryonic stem cells lack the ability to repair double strand breaks by homologous recombination (Snouwaert et al., 1999) .
Several lines of evidence support a role for BRCA1 as a tumour suppressor. Studies in breast cell lines found that over expression of BRCA1 inhibits cell growth and induces apoptosis (Shao et al., 1996) , while inhibition of BRCA1 expression by the introduction of antisense oligonucleotides into cells derived from an ovarian carcinoma increases cell proliferation and causes reduced cell susceptibility to apoptosis (Husain et al., 1998; Shao et al., 1996) . Furthermore, in the familial form of breast cancer loss of heterozygosity was observed at the BRCA1 locus in a very high percentage of individuals which carry mutations of this gene (Neuhausen and Marshall, 1994) . In the sporadic form of breast cancer, no mutation in the coding gene or the promoter region of BRCA1 have been identi®ed (Futreal et al., 1994; Merajver et al., 1995) . Nevertheless, down regulation of expression of this gene occurs in a signi®cant percentage of cases, suggesting that transcriptional regulation of BRCA1 is involved in the transformation process and in the etiology of sporadic breast cancer (Thompson et al., 1995) .
Studies of the BRCA1 promoter region revealed a TATA-less promoter divergent with the adjacent NBR2 gene (Xu et al., 1997) . A second BRCA1 promoter downstream can give rise to an alternative ®rst exon (1B) (Xu et al., 1995) , however a recent study was unable to con®rm the existence of this second promoter (Suen and Goss, 1999) . Optimal transcriptional activity of the BRCA1 promoter was mapped to a region of 226 bp starting immediately upstream of the 1A transcript of BRCA1 (Xu et al., 1997; Thakur and Croce, 1999) . Within this region, a positively acting site was localized (Thakur and Croce, 1999), which we identi®ed as a GABPa/b binding site, and which is referred to as the RIBS element (Atlas et al., 2000) .
One mechanism by which tumor suppressor genes may be down regulated is via methylation of CpG dinucleotides in the promoter region, and BRCA1 appears to be subject to this type of repression (Rice et al., 1998) . Several reports have shown that methylation of the BRCA1 promoter region correlated with decreased BRCA1 levels at the protein, as well as the mRNA level, and was also correlated with low levels of estrogen receptor (ER) in the tumour samples (Dobrovic and Simpfendorfer, 1997; Magdinier et al., 1998; Catteau et al., 1999) . Frequent methylation within a putative cAMP regulatory element binding protein (CREB) site upstream of the exon 1A region has also been reported to occur in a portion of sporadic breast cancer samples (Mancini et al., 1998) . Furthermore, the methylation of this site eliminated the formation of DNA/protein complexes in vitro. Although clearly important in some cases, methylation does not account for the low level of expression of BRCA1 which occurs in the vast majority of sporadic breast cancers (Catteau et al., 1999) , though when it does occur methylation may lead to very low levels of BRCA1 expression (Rice et al., 2000b) .
Our previous studies of the BRCA1 promoter had identi®ed a region of 226 bp upstream of the 1A exon of the gene which produced maximal transcriptional activity in transient transfection assays (Atlas et al., 2000) . Inspection of the sequence of this region revealed the existence of a putative CREB/ATF consensus site consisting of the sequence TTACGTCA at position 7nt 176 to 7nt 169 ( Figure 1a ). It has not been established whether this site is important for normal BRCA1 promoter activity, and whether the factors binding to this element could regulate BRCA1 expression. In order to determine which transcription factor(s) are able to bind to this sequence we performed gel mobility shift assays using a double stranded labelled oligonucleotide containing the sequence TTACGTCATCC (BrCRE), and nuclear extracts from MCF-7 and T-47D cell lines. In extracts from both lines we detected one prominent complex forming with this site and the introduction of a point mutation changing the CpG dinucleotide to ApT (BrCRE M ) eliminated this complex (results not shown). Competition experiments with increasing concentrations of unlabelled BrCRE oligonucleotide and a CRE consensus site oligonucleotide (CRE), signi®cantly reduced binding in extracts from both cell lines, however the addition of the BrCRE M oligonucleotide had less of an eect on binding, though it did compete at higher concentrations (Figure 1b) .
Since members of the AP-1 transcription factor family are able to interact with similar consensus sites as the CREB/ATF family (Hai and Curran, 1991) it was important to establish which transcription factor interacts with the site in the BRCA1 promoter. To identify the transcription factors which form the complexes observed in the bandshift assay, a supershift gel mobility assay was performed using antibodies to CREB/ATF-1, c-Jun and c-Fos (Figure 2) . A supershift was observed with an antibody which recognizes CREB or ATF-1 (Figure 2 , S.S) and resulted in the complete shift of the lower complex, in both cell lines.
The other antibodies did not produce a supershift. These results clearly indicate that the transcription factor which binds to BrCRE consists entirely of a homodimer or heterodimer comprised of CREB and/or ATF-1.
In order to examine the importance of the CRE site for the activity of the promoter a construct containing the same mutation as the BrCRE M oligonucleotide was created in the BRCA1 proximal promoter and then cloned into the luciferase reporter plasmid pGL 2 vector. This construct (L6CRE-M) was used in transient transfection assays in MCF-7, T-47D and in Figure 1 (a) The nucleic acid sequence of the BRCA1 proximal promoter is shown, with the transcriptional start site indicated by the right pointing arrow. EcoRI and SacI sites present in the BRCA1 sequence are shown in heavy underlining, as is the HindIII site introduced into the 3' end in order to allow for cloning into the reporter plasmid. The CREB site is shown boxed as is a putative CCAAT box. The double stranded oligonucleotides used to carry out the bandshift reactions are shown below the schematic with the wildtype (BrCRE) and mutant (BrCRE M ) sequences illustrated. The CpG which is methylated is boxed in the case of the BrCRE while the mutant bases are boxed in the BrCRE M sequence. (b) Competition bandshift assay with wildtype and mutant oligonucleotides. One nanogram of the radiolabelled BrCRE probe (as indicated above) was used in bandshift assays with nuclear extracts derived from MCF-7 or T-47D breast cell lines as previously described (Armstrong et al., 1997) . The indicated amounts (ng COMP.) of the unlabelled BrCRE, BrCRE M , or a CRE consensus site oligonucleotides from the somatostatin promoter (5'-AGAGATTGCCTGACGTCAGA-GAGCTAG-3') (Montminy and Bilezikjian, 1987) were added to the reactions before the addition of protein. The locations of the bound (B) and free (F) probe DNA are indicated a human liver cell line, Hep G2, and compared with a construct containing the wildtype proximal promoter region (L6). Replacement of the CpG with ApT in the CRE site resulted in 20, 40 and 25% of the wildtype promoter activity in each respective cell line as measured by luciferase activity (Figure 3) . These results show that this site is critical for basal BRCA1 promoter activity in the cell lines tested.
Members of the CREB/ATF family of transcription factors are known to be activated by phosphorylation in response to changes in cAMP levels (De Cesare et al., 1999) . We investigated the activity of the L6 and L6CRE-M promoters in response to the protein kinase-A (PKA) activator forskolin. A plasmid containing a multimerized CREB site (pCRE-luc) was used as a positive control for cAMP responsiveness. The addition of forskolin to transiently transfected cells resulted in no activation of the L6 or L6CRE-M constructs in MCF-7 and T-47D cell lines, and repression in the Hep G2 line (Figure 3) . The CREmultimer (pCRE-luc) showed signi®cant activation in MCF-7 (12-fold) and Hep G2 cells (fourfold), though T-47D cells appear to not be cAMP responsive, despite being able to demonstrate phosphorylation of CREB in these cells after forskolin treatment (results not shown).
These results suggest that the BRCA1 promoter is not cAMP responsive, in agreement with previous observations (Suen and Goss, 1999) , and that in this context the CREB site behaves as a constitutive rather than an inducible element in both breast and liver cells.
Changes in the transcriptional regulation of BRCA1 may be an important aspect in the initiation or progression of sporadic breast cancer given the consistent decrease in BRCA1 expression observed in tumour samples. This implies that transcriptional mechanisms regulating BRCA1 expression may be aected in these tumours. Methylation of the BRCA1 promoter has been suggested as a possible mechanism for down regulating BRCA1 expression (Mancini et al., 1998; Magdinier et al., 1998; Dobrovic and Simpfendorfer, 1997; Rice et al., 1998) , in at least a limited subset of sporadic breast tumours (Catteau et al., 1999) . The CREB site contains a CpG dinucleotide which is often, though not exclusively, methylated in those tumours exhibiting promoter methylation (Mancini et al., 1998) . In tumours in which the BRCA1 promoter is methylated, these promoters have been shown to be in a condensed chromatin state and the constituent histones are hypoacetylated (Rice and Futscher, 2000a) . In vitro methylation of the BRCA1 promoter and cotransfection of methyl-CpG binding proteins such as MeCP2 result in reduced BRCA1 expression (Magdinier et al., 2000) . In vitro methylation of the CREB site has also been shown to block the binding of CREB protein (Mancini et al., 1998) . The strong constitutive role for the CREB site in BRCA1 promoter function suggests that methylation of this site would have a profound eect on expression of BRCA1 and would be consistent with the particularly low levels of BRCA1 expression observed in tumours in which methylation has occurred .
Identi®cation of a functional CREB/ATF-1 site in the BRCA1 promoter would normally be an indication that expression of the gene could be regulated by the cAMP/protein kinase A pathway. We have been able to demonstrate that it is likely a mixture of both CREB and ATF-1 which interacts with the BrCRE in the proximal promoter in two human breast cancer cell lines. Despite being able to show increased phosphorylation of these factors in response to treatment with forskolin (results not shown), no stimulation of BRCA1 expression was seen. Other promoters have also been shown to be cAMP inducible in these cell lines (Dong et al., 1999) and a CRE multimer reporter construct is also highly inducible. These results suggested that due to the nature of the promoter context, the CREB site does not mediate inducible expression. The CREB site is in close proximity to a GABPa/b site which we have previously characterized as being critical for BRCA1 promoter function, and which is dierentially regulated in MCF-7 and T-47D cell lines (Atlas et al., 2000) . A previous study has suggested that functional interaction can occur between these two factors (Sawada et al., 1999) , which we postulate might have an eect on cAMP responsiveness. The interaction of CREB with Sp1 has been Figure 2 Supershift assays of the BrCRE probe. Bandshift assays with the BrCRE probe and nuclear extracts from either T-47D of MCF-7 cell lines were carried out as in Figure 1 , followed by the addition of 2 ml of rabbit anti-CREB, anti-Fos or anti-Jun polyclonal antibodies (Santa-Cruz) and incubation for 45 min on ice. The location of the free DNA (F), the bound complex (B), or the supershifted complex (S.S) is shown shown to be important for the constitutive expression of the Na,K-ATPase a1 subunit (Kobayashi and Kawakami, 1997) as has interaction with NF-Y in the insulin gene (Eggers et al., 1998) . However, in both of these examples some cAMP responsiveness is retained, though higher basal promoter activity appears to be correlated with decreased cAMP responsiveness. Thus stabilization of CREB by its partners may result in constitutive expression. The question also remains as to why a potentially regulated transcription factor such as CREB would be used as a constitutive element in the BRCA1 promoter? It may be that under certain circumstances during development or in speci®c tissues, there is a need for such regulation. Perhaps, in the absence of factors binding to other sites in the BRCA1 promoter, the promoter becomes cAMP responsive. Studies of this promoter in other contexts will be required in order to address this issue. Figure 3 Activity and forskolin inducibility of the wildtype and mutant BRCA1 promoters. The wildtype proximal BRCA1 promoter (L6), or a mutant in the CREB site (L6CRE-M), or a CRE multimer construct (Stratagene) were transfected into T-47D, MCF-7 or Hep G2 cells. The L6 proximal promoter in pGL2-basic was previously described (Atlas et al., 2000) . Site directed mutagenesis of the CREB site was carried out by PCR using Vent polymerase (New England Biolabs, Inc., USA) according to the manufacturer's instructions, using the primers: the upstream primer L6-5' 5'-GGGCTAGCGAATTCTTCCTCTTCCG, the mutant primers L6CR Mut +5'-TTTTAATTCATCCGGGGG-3', and L6CR
Mut 7 5'-CCCGGATGAATTAAAAGG-3', and the 3' primer 5'-GGAAGCTTGAGCTCACGCCGCGC-3'. The PCR product was digested with NheI and HindIII before cloning into the pGL2-basic Luciferase reporter vector (Promega). Transfection was using FuGENE (Boehringer-Mannheim) according to the manufacturer's instructions, and included pRL-TK or pRL-CMV (Promega) as internal controls. The cells were incubated with the DNA for 24 h, followed by replacement of the medium with fresh culture medium containing 0.5% foetal bovine serum. For the activation of the cAMP pathway the cells were treated with 20 mM forskolin (shaded bars) or DMSO (open bars) for 24 h. In all cases, 48 h post-transfection the cells were assayed using the dual luciferase kit according to the manufacturer's recommendations (Promega). The internal control was used to normalize between samples, which were done as three independent replicates. The normalized values are expressed as relative light units, and the average and standard deviation of the three replicates are shown. These results are typical of at least three separate experiments
